OxfordBioTherapeutics
Location: United Kingdom, England, Oxford
Total raised: $20M
Founded date: 2004
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 26.01.2017 | - | $10M | - |
| 30.07.2015 | - | $10M | - |
Mentions in press and media 16
| Date | Title | Description |
| 22.06.2026 | Oxford BioTherapeutics’ Third Partnered Programme with Boehringer Ingelheim Enters the Clinic and its First (Obrixtamig) Advances to Phase 3 | - First patients dosed with BI 3820768 (OB33), marking third programme from the Oxford BioTherapeutics (OBT)-Boehringer Ingelheim collaboration to enter clinical development - Obrixtamig reaches late-stage development triggering milestone p... |
| 09.04.2026 | Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours | ▪ Collaboration leverages OBT's proprietary OGAP®-Verify discovery platform and drug development capabilities in alignment with BMS’s expertise to advance selected novel oncology targets ▪ This is OBT’s third major pharma collaboration with... |
| 10.12.2025 | Oxford BioTherapeutics Enters into a Strategic Collaboration with GSK to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer | ▪ Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targets ▪ The agreement - OBT's second high-profile pharma collaboration this year - reflects... |
| 07.03.2024 | Oxford BioTherapeutics Announces Launch of Enhanced Discovery Platform, OGAP®-Verify, at World ADC Conference 2024 | - |
| 03.10.2022 | Oxford BioTherapeutics enters into Commercial License Agreement with Genmab | • OBT licenses to Genmab the rights to a novel, pre-clinical first-in-class immuno-oncology (IO) antibody. |
| 07.04.2022 | AACR 2022: Oxford BioTherapeutics to Present Potential Novel Immuno-Oncology Mechanism in Combination with Checkpoint Inhibitors for Experimental ADC Medicine OBT076 | AACR 2022: Oxford BioTherapeutics to Present Potential Novel Immuno-Oncology Mechanism in Combination with Checkpoint Inhibitors for Experimental ADC Medicine OBT076 |
| 01.04.2021 | San Jose BioCube Embarks on Next Phase of Plan to Attract the Next Generation of Scientists | BioCube's new facility blends highly advanced biotech workplace environments with a modern lab design and beautiful architectural elements that feature space, natural light, greenery, and glass. BioCube’s mission is to attract and retain th... |
| 19.01.2021 | Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform | OXFORD, United Kingdom and SAN JOSE, Calif. and SHANGHAI, China, Jan. 19, 2021 (GLOBE NEWSWIRE) -- WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading open-access biologics technology platforms, and Oxford BioTherapeutics L... |
| 06.01.2021 | Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors | Santa Monica, Calif.; Oxford, UK; and San Jose, Calif., January 6 2021 - Kite, a Gilead Company (Nasdaq: GILD), and Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-dr... |
| 14.10.2020 | Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic | The collaboration for the discovery of novel selective tumor targets for Boehringer Ingelheim’s unique T-cell engager, cancer vaccine and oncolytic virus platforms, enabled by Oxford BioTherapeutics’ proprietary OGAP® (Oxford Genome Anatomy... |
Show more